Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

tranexamic acid injection (Rx)Brand and Other Names:Cyklokapron

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 100mg/mL
more...

Dental Extraction in Patients with Hemophilia

Indicated in patients with hemophilia for short-term use (ie, 2-8 days) to reduce/prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction

10 mg/kg IV immediately before surgery OR 10 mg/kg IV q6-8hr 1 day before surgery 

25 mg/kg PO q6-8hr 1 day presurgery AND 2-8 days postsurgery

CABG (Off-label)

10-15 mg/kg IV over 20 minutes, THEN 1 mg/kg/hr continuous infusion for 6-10 hours 

Hereditary Angioedema (Off-label)

Long-term prophylaxis: 1000-1500 mg PO q8-12hr; reduce dose to 500 mg/dose PO qDay or q12hr when frequency of attacks reduces

Short term prophylaxis: 75 mg/kg/day PO divided q8-12hr for 5 days before and after the event 

Treatment of acute HAE attack: 25 mg/kg/dose PO/IV; not to exceed 1000 mg/dose q3-4hr; not to exceed 75 mg/kg/day or 1000 mg PO q6hr for 48 hr

Total Knee Replacement Surgery, Blood Loss Reduction (Off-label)

10 mg/kg IV over 30 min before inflation of tourniquet and 3 hr after first dose 

Hyphema (Off-label)

25 mg/kg PO q8hr for 5-7 days 

Renal Impairment

Dental Extraction

  • SCr 1.36-2.83 mg/dL (120-250 micromoles/L): 10 mg/kg IV q12hr OR 15 mg/kg PO q12hr
  • SCr 2.83-5.66 mg/dL (250-500 micromoles/L): 10 mg/kg IV qDay OR 15 mg/kg PO qDay
  • SCr >5.66 mg/dL (>500 micromoles/L): 10 mg/kg IV q48hr OR 15 mg/kg PO q48hr; alternatively, 5 mg/kg IV qDay OR 7.5 mg/kg PO qDay

Dosage Forms & Strengths

injectable solution

  • 100mg/mL
more...

Dental Extraction in Patients with Hemophilia

10 mg/kg IV immediately before surgery OR 10 mg/kg IV q6-8hr 1 day before surgery

25 mg/kg PO q6-8hr 1 day presurgery AND 2-8 days postsurgery

Hyphema (Off-label)

25 mg/kg PO q8hr for 5-7 days

Hereditary Angioedema (Off-label)

Long term prophylaxis: 20-40 mg/kg/day PO divided q8-12hr; reduce dosing frequency to every other day or twice weekly when frequency of attacks reduces

Short term prophylaxis: 20-40 mg/kg/day PO divided q8-12hr; initiate 2-5 days before and continue for 2 days after the procedure

Next

Interactions

Interaction Checker

tranexamic acid injection and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Visual abnormalities

            Hypotension (with rapid injection)

            Nausea

            Vomiting

            Diarrhea

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity

            Acquired defective color vision

            Subarachnoid hemorrhage

            Active intravascular clotting

            Cautions

            Use caution in renal impairment, subarachnoid hemorrhage, vascular disease

            DIC

            Visual defects (color vision change or visual loss) reported

            Thrombembolic history

            Ureteral obstruction resulting from clot formation reported; use caution in patients with upper urinary tract bleeding

            Thromboembolism or venous and arterial thrombosis reported

            Ligneous conjunctivitis has been reported

            Concurrent use with anti-inhibitor coagulant complex/factor IX complex concentrates

            Concurrent use with tretinoin may exacerbate procoagulant effects

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Excreted in breast milk, not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Inhibits fibrinolysis by displacing plasminogen from fibrin

            Reduces plasmin activity, which in turn reduces activation of complement and consumption of C1 esterase inhibitor (C1-NH) and subsequently decreases inflammation associated with hereditary angioedema

            Pharmacokinetics

            Half-Life: 2-11 hr

            Duration: 3 hr (after 1 dose)

            Peak Plasma time: 3 hr

            Plasma concentration: 15 mg/L

            Protein Bound: 3%

            Vd: 9-27 L

            Clearance: 110-116 mL/min

            Excretion: Urine (95%)

            Previous
            Next

            Administration

            IV Incompatibilities

            Additive: blood, penicillin

            IV Compatibilities

            Solution: compatible with most common solutions for infusion

            Additive: heparin

            IV Preparation

            Prepare solution same day it will be used

            Dilute a single dose w/t 50 mL compatible fluid (eg, NS, Ringers, dextrose/water)

            IV Administration

            100 mg or fraction thereof over at least 1 min, usu 5 min

            Avoid rapid infusion

            Storage

            Store at 25°C (77°F)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.